Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

deseret biologicals, inc. - berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), milk thistle (unii: u946sh95ee) (milk thistle - unii:u946sh95ee), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - unii:7e889u5rnn), glycyrrhiza glabra (unii: 2788z9758h) (glycyrrhiza glabra - unii:2788z9758h), arctium lappa root (unii: 597e9bi3z3) (arctium lappa root - unii:597e9bi3z3), frangula alnus bark (unii: s2d77ih61r) (frangula alnus bark - unii:s2d77ih61r), stillingia sylvatica root (unii: - for temporary relief of symptoms related to toxicity caused by environmental substances including neck pain, hives, occasional constipation, cough, and headache.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to toxicity caused by environmental substances including neck pain, hives, occasional constipation, cough, and headache.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

deseret biologicals, inc. - berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), milk thistle (unii: u946sh95ee) (milk thistle - unii:u946sh95ee), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - unii:7e889u5rnn), glycyrrhiza glabra (unii: 2788z9758h) (glycyrrhiza glabra - unii:2788z9758h), arctium lappa root (unii: 597e9bi3z3) (arctium lappa root - unii:597e9bi3z3), frangula alnus bark (unii: s2d77ih61r) (frangula alnus bark - unii:s2d77ih61r), stillingia sylvatica root (unii: - for temporary relief of symptoms related to toxicity caused by environmental substances including neck pain, hives, occasional constipation, cough, and headache.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to toxicity caused by environmental substances including neck pain, hives, occasional constipation, cough, and headache.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bioactive nutritional, inc. - triticum aestivum whole (unii: 3c3y389jbu) (triticum aestivum whole - unii:3c3y389jbu), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), arctium lappa root (unii: 597e9bi3z3) (arctium lappa root - unii:597e9bi3z3), frangula purshiana bark (unii: 4vbp01x99f) (frangula purshiana bark - unii:4vbp01x99f), senna leaf (unii: ak7jf626kx) (senna leaf - unii:ak7jf626kx), phytolacca americana root (unii: 11e6vi8veg) (phytolacca americana root - unii:11e6vi8veg), gl - for temporary relief of head congestion & general exhaustion as a consequence of exposure to smog, dust, or industrial agents. for temporary relief of head congestion & general exhaustion as a consequence of exposure to smog, dust, or industrial agents.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 29.8 g in 1000 ml - potassium chloride injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. this highly concentrated, ready-to-use potassium chloride injection is intended for the maintenance of serum k+ levels and for potassium supplementation in fluid restricted patients who cannot accommodate additional volumes of fluid associated with potassium solutions of lower concentration. when using these products, these patients should be on continuous cardiac monitoring and frequent testing for serum potassium concentration and acid-base balance. potassium chloride injection is contraindicated in patients with:

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - sodium chloride 0.9 g in 100 ml - potassium chloride in 0.9% sodium chloride injection is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. potassium chloride in 0.9% sodium chloride injection is contraindicated in clinical conditions where additives of sodium, potassium or chloride could be clinically detrimental.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - attention deficit disorder with hyperactivity: methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of methamphetamine hydrochloride tablets, hypersensitivity reactions such as angioedema and anaphylactic reactions have been re

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

mayne pharma commercial llc - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of methamphetamine hydrochloride tablets. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetami

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

wockhardt usa llc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 100 mg - bupropion hydrochloride extended-release tablets (sr) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm) . the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with mdd [see clinical studies (14)] . the efficacy of bupropion hydrochloride extended-release tablets (sr) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial [see clinical studies (14)] . - bupropion hydrochloride extended-release tablets (sr) are contraindicated in patients with a seizure disorder. - bupropion hydrochloride extended-release tablets (sr) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies (14.1)]. bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets (xl) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials i

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 2 meq in 1 ml - potassium chloride for injection concentrate, usp is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. potassium chloride for injection concentrate is contraindicated in diseases where high potassium levels may be encountered, and in patients with hyperkalemia, renal failure and in conditions in which potassium retention is present.